PASK (Proline-Alanine-rich STE20-related Kinase), a Regulatory Kinase of the Na-K-Cl Cotransporter (NKCC1)*

Brian F. X. Dowd {ddagger} and Biff Forbush

From the Yale University, School of Medicine, Department of Cellular and Molecular Physiology, New Haven, Connecticut 06520-0826

Received for publication, February 24, 2003 Accepted for publication May 7, 2003.


    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS AND DISCUSSION
 REFERENCES
 
Although the phosphorylation-dependent activation of the Na-K-Cl cotransporter (NKCC1) has been previously well documented, the identity of the kinase(s) responsible for this regulation has proven elusive. Recently, Piechotta et al. (Piechotta, K., Lu, J., and Delpire, E. (2002) J. Biol. Chem. 277, 50812–50819) reported the binding of PASK (also referred as SPAK (STE20/SPS1-related proline-alanine-rich kinase)) and OSR1 (oxidative stress response kinase) to cation-chloride cotransporters KCC3, NKCC1, and NKCC2. In this report, we show that overexpression of a kinase inactive, dominant negative (DN) PASK mutant drastically reduces both shark (60 ± 5%) and human (80 ± 3%) NKCC1 activation. Overexpression of wild type PASK causes a small (sNKCC1 22 ± 8% p < 0.05, hNKCC1 12 ± 3% p < 0.01) but significant increase in shark and human cotransporter activity in HEK cells. Importantly, DNPASK also inhibits the phosphorylation of two threonines, contained in the previously described N-terminal regulatory domain. We additionally show the near complete restoration of NKCC1 activity in the presence of the protein phosphatase type 1 inhibitor calyculin A, demonstrating that DNPASK inhibition results from an alteration in kinase/phosphatase dynamics rather than from a decrease in functional cotransporter expression. Coimmunoprecipitation assays confirm PASK binding to NKCC1 in transfected HEK cells and further suggest that this binding is not a regulated event; neither PASK nor NKCC1 activity affects the association. In cells preloaded with 32Pi, the phosphorylation of PASK, but not DNPASK, coincides with that of NKCC1 and increases 5.5 ± 0.36-fold in low [Cl]e. These data conclusively link PASK with the phosphorylation and activation of NKCC1.


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS AND DISCUSSION
 REFERENCES
 
The phosphorylation of the N terminus of the secretory or housekeeping isoform of the Na-K-Cl cotransporter (NKCC1)1 has been previously shown to confer its activation in numerous experimental systems using various stimuli (1, 2). Our current model suggests a low intracellular chloride concentration and/or a reduction in cell volume as the principle stimulus for NKCC1 activation. The kinase(s) mediating this activation, however, has remained obscure.

Our laboratory has previously identified three threonines on the N terminus of the Na-K-Cl cotransporter that modulate activity, highlighting Thr189 (numbering in shark) as essential for cotransporter function (3). A phosphospecific antibody specifically recognizes two of these phosphothreonines (Thr184, Thr189) and has proven to be a powerful tool in discerning the activation state of NKCC1 in cells and tissue (4). This regulatory domain resides in one of three highly conserved regions on the N terminus and was shown to mediate the activation of NKCC1 in species ranging from shark to human (4). Another of these N-terminal conserved regions has recently been identified by our laboratory as a protein phosphatase type 1 binding site (RVXFXD) (5). Mutation of this site to either enhance or disrupt protein phosphatase type 1 binding significantly alters the activation profile of NKCC1.

Recently, the significance of the third conserved domain in the NKCC1 N terminus was suggested by studies of Piechotta et al. (6). This 10-amino acid region contains an (R/K)FX(V/I) sequence that was found to bind the proline alanine-rich STE20-related kinase (PASK) and the highly homologous (67% identical) oxidative stress response kinase (OSR1) in yeast two-hybrid and GST pull-down assays. An additional binding motif is found 54 residues downstream (6), overlapping the previously described protein phosphatase type 1 binding site (5). To date no functional effect of PASK upon NKCC1 has been identified. The direct binding of this kinase, possibly with the resultant disruption of its regulatory phosphatase, made PASK an attractive candidate for NKCC regulation. In addition, the high expression of PASK in solute-transporting epithelia (7) parallels that of NKCC1.

A number of protein kinases have been previously discussed in conjunction with NKCC1 activation. Human NKCC1 contains known consensus phosphorylation sites for protein kinase C, casein kinase II, and protein kinase A, but none of these has been directly linked to NKCC1 activation. The inhibition of myosin light chain kinase has been shown to inhibit NKCC1 function, but it does not affect NKCC1 phosphorylation and has been proposed to act indirectly through cytoskeletal disruption (8). Serum- and glucocorticoid-dependent kinase has been suggested to mediate an increase in NKCC1 activity via an increase of cotransporter insertion into the cell membrane but has not been shown to directly activate functional NKCC1 (9). c-Jun N-terminal kinase has also been proposed as an NKCC1 regulatory kinase candidate; to date, however, this has only been supported by in-gel kinase assays (10).

PASK (also referred as SPAK2 (STE20/SPS1-related, proline alanine-rich kinase (11)) is a 55-kDa serine/threonine kinase within the germinal center kinase VI subfamily of STE20 group kinases (12). First isolated from rat brain, PASK was found to be heavily expressed in epithelial cells active in ion transport and to associate with the cytoskeleton (7). The only demonstrated biological function for this kinase was reported for Fray, the Drosophila PASK homologue, which was shown to be expressed in glial cells and required for the proper ensheathing neighboring axons (13).

In this report, we describe the regulation of NKCC1 by PASK in transfected HEK cells. We show that overexpression of PASK causes a small but significant increase in NKCC1 activity. We also show that a dominant-negative PASK mutant drastically inhibits shark and human NKCC1 activation. This inhibition is via a decrease in NKCC1 regulatory phosphorylation, not a decrease in number of functional cotransporter molecules or a down-regulation in expression. We also show that PASK phosphorylation parallels that of NKCC1 in low [Cl]e and that binding of the kinase does not appear to be regulated by or dependent upon the activation state of PASK or NKCC1.


    EXPERIMENTAL PROCEDURES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS AND DISCUSSION
 REFERENCES
 
cDNA Constructs and the Production of Stable Cell Lines—The rat PASK clone was HA-tagged on the N terminus and subcloned into the pIRES puro3 vector (Invitrogen) using PCR. Briefly, a forward primer (p1) containing the HA antigen and EcoR1 site (ggaattccatgtacccatacgacgtcccagactacgctATGGCGGAGCCGAGCGGCTCG) (the PASK sequence is in uppercase) and reverse primer (p2) containing a stop codon and BamH1 site (cgggatccTCAGCTCACACTCAACTGGGCGAAC) were used in a PCR reaction with pGST-PASK as a template (a kind gift of William Leiserson) (7). The PCR product was then subcloned into the pIRES puro3 vector using EcoR1 and BamH1.

The dominant negative, kinase inactive K101R PASK was created using a two-step PCR approach. First, an internal primer (p3) (CGCGTAGCCATAAgGCGGATCAACTTG) and its reverse complement (p4) (CAAGTTGATCCGCcTTATGGCTACGCG) were created containing a single nucleotide substitution to produce the K101R mutation (mutation in lowercase). PCR reactions were completed using p1/p4 and p2/p3 primer combinations. After gel purification of the two products, equal amounts were subjected to five cycles of PCR with Pfu polymerase but without primers (for extension). The p1 and p2 primers were then added to amplify the full-length mutant. Subcloning into pIRES puro3 (Clontech) was completed as described above. Sequence verification was completed by the Mount Desert Island Biological Laboratory DNA Sequencing Center.

For most experiments a shark protein kinase (sMST1/2)3 with significant homology to mammalian MST1 (accession number AAA83254 [GenBank] ) and MST2 (accession number 2204254A) was used as a control in addition to vector-transfected cells. We identified MST1/2 in an expression screen of a {lambda} phage shark kidney library. This kinase identification assay was adapted from a method previously described by Matsuo et al. (14). Using the previously described phosphospecific Thr184/Thr189 NKCC antibody (R5) (4) candidates were selected for their ability to phosphorylate a 15-amino acid GST fusion tandem-repeat protein containing the Thr184/Thr189 residues residing within the previously described N-terminal regulatory domain of NKCC1 (GST-YYLRTFGHNTMDAVP YYLRTFGHNTMDAVP; the Thr residues in shown bold are at positions 184, 189, 184, and 189, respectively). MST1/2 was identified in this screen, but subsequent experiments failed to support an important role for the kinase in NKCC1 regulation, and we have utilized it as a control enzyme in the current study. Interestingly, like PASK, MST1/2 is a member of the germinal center kinase family of STE20 kinases. In addition, the kinase domain of MST1/2 retains a high homology (40%) to PASK, and both kinases contain putative caspase 3 cleavage sites and nuclear localization signals (11).

IRES puro3 vector (Clontech) containing PASK, dominant negative mutant (DNPASK), or shark MST1/2 were transfected with LipofectAMINE 2000 (Invitrogen) into various HEK stable clonal cell lines, all carrying the Geneticin resistance marker and previously described (15, 16). Cells were selected and maintained in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum, 1 µg/ml puromycin (Clontech), and 0.8 mg/ml Geneticin (Invitrogen). With the use of the IRES vector, clonal selection was not needed in isolation of stable lines. The IRES vector is herein referred to as "vector 2," whereas the pJB20 vector used for sNKCC1 and hNKCC1 expression is referred to as "vector 1."

86Rb+ Influx Assays—Influx assays to assess NKCC1 cotransport activity were performed as previously described using an automated 96-well plate flux machine (3). For calyculin A time courses, the compound was dissolved in Me2SO and diluted into the appropriate preincubation media with a final concentration of ~500 nM at specific time points before the flux assay. The flux time was 2 min for exogenously expressed cell lines (sNKCC1 and hNKCC1) and 8 min for the measurement of endogenous NKCC1 activity.

32P Incorporation and Coimmunoprecipitation Experiments—Near confluent 10-cm dishes were rinsed with phosphate-free isotonic media (135 mM NaCl, 5 mM RbCl, 1 mM CaCl2/MgCl2, and 15 mM NaHEPES, pH 7.4) and incubated with 250 µCi of 32Pi for 20 min. Cells were then rinsed 2x with either phosphate-free isotonic or phosphate-free 3 mM Cl with gluconate replacement (135 mM sodium gluconate, 5 mM potassium gluconate, 1 mM CaCl2, 1 mM MgCl2, 1 mM Na2HPO4, 1 mM NaSO4) media for 1 h at room temperature. Cells were lysed on ice in 1 ml of lysis buffer (300 mM NaCl, 50 mM Hepes, 25 mM {beta}-glycerophosphate, 1% Nonidet P-40, 1 mM sodium vanadate, 5 mM EDTA, 0.5 µM calyculin A, protease inhibitor mixture (Roche Applied Science)) and centrifuged to remove debris. Bovine serum albumin (0.25% final concentration) and 5 µg of antibody were added before a 2-h incubation at 4 °C. Protein G beads (Pierce) were blocked in 5% milk/phosphate-buffered saline, 0.1% Tween 20, washed in lysis buffer, added to lysate, and incubated at 4 °C for an additional hour. Immunocomplexed beads were washed 3x in ice-cold wash buffer (lysis buffer without calyculin A and protease inhibitors) and 1x in ice-cold phosphate-buffered saline. Sample buffer with 2-mercaptoethanol was added before boiling. Samples were then subjected to SDS-PAGE using a 10% acrylamide gel. Western blotting was completed as previously described (4). For protein determinations of 96-well flux plates, cells were solubilized with 1% SDS after being exposed to phosphorimaging plates, and the DC-BCA kit (Pierce) was used according to the manufacturer's instructions.

In the post-lysis binding experiment, immunoprecipitation was conducted as described above except for the following changes; after lysis and centrifugation, 200 µl of HEK cell lysate was added to 200 µl of vector 1/PASK, sNKCC1/vector 2, or sNKCC1/PASK. In a fourth tube, 200 µl of lysate from vector 1/PASK and sNKCC1/vector 2 were combined before the immunoprecipitation step.

Regulatory Phosphorylation Time Course—Transfected HEK cells were grown to confluence in a 96-well polylysine-treated plate. Wells were rinsed with incubation media for specific time points, and the reaction was terminated with the addition of 1 N H3PO4, 1% SDS. Samples were neutralized with 3 M Tris, 1 N NaOH and loaded in duplicate onto two separate gels. SDS-PAGE with Western analysis using the phosphospecific R5 and J3 antibodies was completed in parallel. Comparison of parallel blots was necessary due to selective loss of signal on stripping.

Antibodies—The sNKCC1-specific J3 antibody and R5 phospho-specific NKCC have been previously described (1, 4). Polyclonal (MBL) and monoclonal (Roche Applied Science) anti-HA antibodies were purchased.

General—All incubations were carried out at room temperature (21–24 °C) unless otherwise noted. Data are presented as the means ± S.E. from replicate experiments except as noted (Fig. 1). Statistical significance was determined for summary data by the paired t test (data related to Figs. 1 and 2) or Wilcoxon paired rank test (data related to Fig. 4).



View larger version (31K):
[in this window]
[in a new window]
 
FIG. 1.
The effect of PASK and DNPASK on the activation of NKCC1 cotransport. A, phosphorimage of 86Rb+ influx assays using HEK-hNKCC1 clonal cell line transfected with vector 2 DNPASK, or PASK. Confluent cells in a 96-well plate were assayed in a 2-min 86Rb influx after a 60-min preincubation in media of various Cl concentrations and tonicities, as noted. [Cl] was altered isotonically with gluconate replacement. Hypo/1.5 Cl is a 3 mM Cl solution diluted 1:1 with H2O. Furosemide (Furo, 50 µM) was added to stated preincubation solutions to inhibit NKCC1-mediated restoration of [Cl]e and was removed by rinsing immediately before the flux. B and C, graphical representation of similar experiments with hNKCC1 (B) or sNKCC1 (C) (vector 2 ({circ}) PASK ({blacktriangleup}) DNPASK ({blacktriangledown})). Data shown are the means of 12 replicate wells ± S.D. from a single representative experiment; similar data, summarized in the text, were obtained in 13 other experiments with hNKCC1 and 5 other experiments with sNKCC1.

 


View larger version (30K):
[in this window]
[in a new window]
 
FIG. 2.
The effect of PASK and DNPASK on NKCC1 regulatory phosphorylation. A, the time course of NKCC1 activation was measured using the anti-phospho-NKCC1 antibody (R5; top four rows). Before lysis, cells were incubated in hypotonic (150 mosmol) 1.5 mM Cl for the time noted. The lower band on the R5 blots is believed to represent endogenous hNKCC1 (see Flemmer et al. (4)). The sNKCC1 immunoblot (using the J3 antibody) was utilized as a measure of total NKCC1; Coomassie Blue staining illustrates that there are similar protein levels in the control cells. B, regulatory NKCC1 phosphorylation at three time points, analyzed as the R5/J3 ratio normalized to the vector 2 control within each of four experiments. Differences are significant (p < 0.01) for DNPASK as well as (p < 0.05) for PASK at the 10-min time point and sMST1/2 at the 3-min time point.

 


View larger version (42K):
[in this window]
[in a new window]
 
FIG. 4.
sNKCC1/PASK reciprocal coimmunoprecipitation. Vector 1/PASK or sNKCC1 clonal cell lines transfected with DNPASK, PASK, or vector 2 were preloaded with 32Pi and placed in 3 Cl (+) isotonic buffer or 140 Cl (–) isotonic buffer for 1 h before lysis. sNKCC1- or HA-tagged kinases were immunoprecipitated for 3 h at 4 °C using the J3 antibody or anti-HA antibodies, respectively. A, J3 IP, top panel (i), phosphorimage of Western blot. The upper band represents NKCC1, whereas the lower (lighter) band represents PASK. ii, the same image as in i, cropped with increased contrast, to highlight PASK phosphorylation. Middle panel, Western blot of immunoprecipitated samples probed with a polyclonal anti-HA antibody. The HA signal represents the amount of PASK and DNPASK coimmunoprecipitated with sNKCC1. Bottom panel, J3 blot showing expressed sNKCC1 levels in the immunoprecipitates. B, summary of eight experiments similar to that in A. sNKCC1 32P incorporation is reported as the 32P/J3 signal normalized to sNKCC1/vector 2 (+). C, anti-HA IP. Top panel, phosphorimage of Western blot. The upper band represents NKCC1, the middle band represents PASK, and the lowest band represents sMST1/2. Middle panel, HA blot showing immunoprecipitation levels of exogenously expressed PASK, DNPASK, and sMST1/2. Bottom panel, the Western blot in the middle panel was stripped and probed with a monoclonal anti-sNKCC1 antibody (J3). The J3 signal represents the amount of sNKCC1 coimmunoprecipitated with HA-tagged kinases. D, summary of five similar experiments showing the fold stimulation by low Cl preincubation of 32P incorporation in HA-immunoprecipitated kinases (normalized to the HA signal and the basal activation condition).

 


    RESULTS AND DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS AND DISCUSSION
 REFERENCES
 
To address the effect of PASK activity upon NKCC1 activation, HEK clonal cell lines stably expressing sNKCC1 or hNKCC1 were transfected with PASK or a kinase inactive, DNPASK. This previously described PASK mutation (7, 11), consisting of a single amino acid substitution (K101R), involves an essential lysine residue found within the catalytic domain of most kinases and has been shown to abolish the positioning of the terminal phosphate of ATP (17). sNKCC1 cells were also transfected with the shark homologue of MST1/2 or with a MST1/2 kinase inactive mutant created via a Thr -> Ala mutation in the activation loop of its catalytic domain. This mutation has been previously described to suppress the catalytic activity of MST (18). We identified sMST1/2 in a screen for NKCC1-specific phosphorylation activity, but this kinase does not appear to be significantly involved in NKCC1 regulation (see "Experimental Procedures"); it was used here as a kinase control.

The expression of DNPASK results in a dramatic inhibition of NKCC1 activation in HEK cells. Fig. 1 illustrates the results of several experiments in which 86Rb influx activity was examined in NKCC1-expressing HEK cells transfected with DNPASK, PASK, or vector 2 alone. In these experiments, cotransport activity was activated by preincubation in media of various Cl concentrations, as previously described (5). As shown here, DNPASK expression produced a dramatic decrease in the level of NKCC1 activity for both human (Fig. 1, A and B) and shark (Fig. 1C) cotransporters. Under conditions of maximal activation by preincubation in 3 mM Cl, DNPASK decreased the activity of hNKCC1 by 80 ± 3% in 14 experiments including those of Fig. 1, and it decreased sNKCC1 activity by 60 ± 5% in 6 experiments. This high level of inhibition mediated by the DN mutant strongly suggests that PASK activity is essential for the activation of NKCC1 in HEK cells.

As seen in Fig. 1, overexpression of PASK causes an increase in the activity of NKCC1. Under conditions of maximal activation, the differences were not statistically significant when all of the experiments were analyzed, but at intermediate activation levels the differences were larger. For instance, in the 14 experiments with hNKCC1 and 6 with sNKCC1, after preincubation in 30 mM Cl, the PASK-induced increase in NKCC1 activity was 12 ± 3% (p < 0.01) and 22 ± 8% (p < 0.05), respectively, after each curve was normalized to the maximal activity in 1.5 mM Cl hypotonic conditions. These results are consistent with a situation in which there is sufficient endogenous PASK to fully regulate NKCC1 but in which overexpression of PASK creates a shift toward higher activation at intermediate levels of stimulation. The present data are the first to directly link PASK with the regulation of NKCC1 activity, complementing an earlier study in which PASK binding to NKCC was demonstrated (6).

Previous work in our laboratory has identified an N-terminal regulatory domain in which the phosphorylation state of two threonines (Thr184/Thr189 in shark) correlates with NKCC1 activation (3). To determine whether DNPASK-mediated NKCC1 inhibition also causes a reduction in regulatory phosphorylation, we used the previously described, phosphospecific antibody (R5) raised against two of these phosphorylated threonines (4). As shown in Fig. 2A, overexpression of DNPASK causes a dramatic reduction in the Thr184/Thr189 phosphorylation of sNKCC1 throughout the activation time course; in the four experiments summarized in Fig. 2B, the reduction is 75 ± 8% at the 10-min time point. This result is consistent with the results of 86Rb+ influx assays and it links PASK to both the activation and phosphorylation of NKCC1. As in the 86Rb influx assays, any effect of PASK under conditions of maximal stimulation is small, and statistical significance is achieved in these four experiments only at the 10-min time point (14% increase).

The experiments of Fig. 2 rule out nonspecific interactions like that of the myosin light chain kinase inhibitor ML-7, where inhibition of NKCC1 did not alter the level of NKCC1 phosphorylation (8). Importantly, DNPASK-mediated inhibition of NKCC1 is not due to a decrease in cotransporter expression levels, as shown using the shark-specific sNKCC1 antibody, J3. These data are also consistent with the decrease of sNKCC1 32P incorporation under low [Cl]e conditions (see Fig. 4) and indicate that the action of DNPASK is to prevent phosphorylation of NKCC1.

To further test the action of DNPASK in affecting the NKCC1 phosphorylation state, we measured 86Rb+ influx in the presence of the protein phosphatase type 1 inhibitor calyculin A. We have previously shown that this compound causes a rapid and dramatic increase in NKCC1 activity via the inhibition of the regulatory phosphatase (5). In the experiments depicted in Fig. 3, b–h, transfected cells are preincubated in various [Cl]e or hypo- or hypertonic media before the addition of calyculin A. Independent of the preincubation condition, NKCC1 activity was initially at a very low level in DNPASK cells (triangles) before calyculin A, similar to the result in Fig. 1. Upon the addition of the phosphatase inhibitor, activity is seen to rise to a level similar to that in vector 2 (closed circles) and PASK (open circles) cells. Expressed as the ratio of DNPASK/vector 2 activity at maximal activation (1.5 mM Cl, hypotonic preincubation) in 12 experiments, the restoration of activity was 0.97 ± 0.1% after 16 min in calyculin A. These data clearly confirm that the effect of DNPASK is due to an alteration in phosphorylation/dephosphorylation and not to a nonspecific effect such as a reduction in functional NKCC1 protein levels.



View larger version (26K):
[in this window]
[in a new window]
 
FIG. 3.
The effect of PASK and DNPASK on the time course of activation of hNKCC1 by calyculin A. PASK ({circ}), DNPASK ({blacktriangledown}), and vector 2 (•) cells were preincubated in various media (see the labels within the figures) for a total of 20 min before a 2-min 86Rb+ influx assay. Within this period, calyculin A was added at different times before the flux assay; the time of calyculin A exposure is denoted on the abscissa. 86Rb+ influx is normalized for the protein level in each cell line. Time courses of activation were analyzed by least squares curve-fitting to a single exponential time course (in the case of the control curves, it was assumed that the maximal activity measured in the experiment is Vmax). For PASK, the derived rate constants in control, 30 mM Cl, and hypotonic conditions are 0.046, 0.80, and 0.74 min1, respectively; for DNPASK, they are 0.05, 0.084, and 0.063 min1; and for vector 2, they are 0.028, 0.85, and 0.86 min1. Data shown are from a single representative experiment; the results of this and 11 similar experiments are summarized in "Results" and "Discussion."

 

The preincubation condition for Fig. 3a is 150 mM Cl, 10 mM K+ media; this has previously been used to fully inactivate NKCC1, presumably by raising [Cl]i (1, 5). In each cell line, NKCC1 activity is seen to increase during the incubation with calyculin A; interestingly, the rate of activation is similar for cells transfected with PASK, DNPASK, or vector 2. This result can be explained if PASK activity is completely inhibited in this preincubation condition, implying that the low rate of NKCC1 phosphorylation seen on the addition of calyculin A must be due to another kinase whose identity is yet unknown.

The rates of calyculin A-induced NKCC1 activation were calculated from the data in Fig. 3 for conditions when NKCC1 is inactive (Fig. 3a) and when it is partially activated by preincubation in 30 mM Cl medium (Fig. 3d) or cell shrinkage (Fig. 3g); the derived rate constants are presented in the figure legend. Although there was a greater than 15-fold increase in the rate constant of PASK- and vector 2-transfected cells during incubation in either of the two activation conditions, the DNPASK-transfected cells displayed less than a 2-fold increase in the rate constant of calyculin A-induced NKCC1 activation. This result is consistent with the idea that most of the residual kinase activity in the DNPASK-transfected cells is due to a kinase other than endogenous PASK.

To investigate PASK association with the cotransporter, reciprocal coimmunoprecipitation experiments were carried out in double-transfected HEK cell lines (Fig. 4). sNKCC1 was immunoprecipitated from cell lysate using a shark-specific anti-sNKCC1 antibody (Fig. 4A), or the tagged kinases were immunoprecipitated with an anti-HA antibody (Fig. 4C). Western blotting shows a much higher level of PASK and DNPASK compared with sMST1/2 as control in immunoprecipitates using anti-sNKCC1 (Fig. 4A). Cells not expressing sNKCC1 (vector 1) are also shown as a further control for specificity. These data are consistent with previous GST pull-down experiments (6) and directly demonstrate the co-association of PASK and DNPASK with NKCC1 in a mammalian cell system.

In this experiment we also address the question as to whether PASK activity is necessary for association with sNKCC1. In Fig. 4A, middle panel, we find that both HA-tagged DNPASK and PASK are present in the immunocomplex when precipitated with the anti-sNKCC1 antibody (J3). Although DNPASK levels are significantly less than PASK in the J3 immunoprecipitate, this coincides with a lower expression level of DNPASK (not shown). The reason for this lower level of expression is unclear but possibly represents clonal selection resulting from a DNPASK-induced, negative-selective pressure. The amounts of sNKCC1 that are co-immunoprecipitated with HA-tagged DNPASK and PASK (Fig. 4C, lower panel) are similar in 5 experiments (PASK/DNPASK ratio 1.7 ± 0.4 for stimulated and 1.1 ± 0.3 for unstimulated cells) and appear to reflect the amounts of immunoprecipitated kinase shown in the HA blot (Fig. 4C, middle panel). These results suggest that PASK activity may not be required for PASK binding to NKCC1.

Additionally in this experiment we address whether PASK binding is dependent upon the activation state of NKCC1. Figs. 4, A, middle panel, and C, bottom panel, show that cells preincubated for 60 min in either a low (+) or normal (–) [Cl]e solution before lysis display similar levels of the HA-tagged PASK or DNPASK associated with sNKCC1. The slight increase shown in this figure was not reproducible in the four replicate experiments; the ratio of stimulated to non-stimulated binding was 1.2 ± 0.3 for PASK and 0.8 ± 0.2 for DNPASK. Thus, it appears that the activated state of sNKCC1 is not a prerequisite for, or consequence of, PASK binding, and the possibility of NKCC1 regulation via a binding competition between protein phosphatase type 1 and PASK seems unlikely.

The cells used in this coimmunoprecipitation experiment were preloaded with 32Pi to measure phosphate incorporation into both the kinase and the cotransporter. Stimulation of NKCC1 under these conditions is confirmed in Figs. 4, A, top panel, i, and B by the increase in phosphorylation in J3 immunoprecipitates. In eight experiments, we found a 64 ± 3% DNPASK-mediated reduction in NKCC1 phosphorylation under stimulatory conditions. The reduction in phosphorylation mirrors the 68% inhibition of transport activity of sNKCC1 activity reported above (e.g. Fig. 1C), and it is consistent with the ~75% inhibition of regulatory phosphorylation seen with the phosphospecific R5 antibody (Fig. 2B). No significant changes in NKCC1 phosphorylation were seen in PASK (1.01 ± 0.20-fold, n = 8)- or sMST1/2 (1.01 ± 0.14-fold, n = 8)-transfected cells, consistent with the above-noted lack of significant differences in flux activity under maximally activating conditions.

Also in this experiment we investigated whether PASK phosphorylation coincides with NKCC1 activation. The activation requirements for PASK have not been previously reported. In Fig. 4C, upper panel, middle band, PASK immunoprecipitated with the anti-HA antibody displays a dramatic increase of 32P incorporation in cells incubated for 60 min in low [Cl]e before lysis; this change was 5.5 ± 0.4-fold in 5 experiments (Fig. 4D). The change in the phosphorylation of immunoprecipitated DNPASK (1.9 ± 0.6-fold) and sMST1/2 (1.5 ± 0.3-fold) was not significant. These data are mirrored in the level of phosphorylation of the kinase that is coimmunoprecipitated with sNKCC1 (Fig. 4A, upper panel, ii, 4.5 ± 0.5 for PASK; 1.8 ± 0.3 for DNPASK). Our interpretation of this result is that the activity of PASK is necessary for its own phosphorylation.

The above finding suggests that either the kinase undergoes intramolecular autophosphorylation when preincubated in [Cl]e or that PASK activity initiates a positive feedback loop that results in its own phosphorylation by another downstream kinase. Although the former ties the activation of PASK to its phosphorylation, the latter does not. Although an increase in kinase phosphorylation commonly corresponds with an increase in its activity, there are known exceptions; therefore, at this time we cannot link the phosphorylation of PASK with its activation. In Fig. 4A, upper panel, ii), we failed to detect a 32P-labeled band that corresponds with the endogenous PASK in sNKCC1/vector 2 immunoprecipitates. Given the low level of phosphorylation detected even within the overexpressed cell lines, we believe that the level of phosphorylated, endogenous PASK is below the limits of detection in this experiment.

We wondered if post-lysis binding during immunoprecipitation might contribute to the result shown in Fig. 4. To test this, we lysed four separate cell lines, (a) HEK cells exogenously expressing HA-tagged PASK alone, (b) HEK cells exogenously expressing sNKCC1 alone, (c) HEK cells exogenously expressing both sNKCC1 and PASK, and (d) non-transfected HEK cells. Cell lysates of (a), (b), and (c) were then each combined 1:1 with (d) as controls. In a fourth tube, lysate from (a) + (b) was combined before the sNKCC1 immunoprecipitation step. Although binding occurs in the cell line exogenously expressing both PASK and sNKCC1 (c), little binding occurs when lysate from cells singly expressing either sNKCC1 or PASK ((a) + (b)) are combined for the immunoprecipitation (Fig. 5). These data strongly suggest that the observed PASK binding does indeed occur pre-lysis.



View larger version (43K):
[in this window]
[in a new window]
 
FIG. 5.
Examination of post-lysis sNKCC1/PASK binding. J3 immunoprecipitation, immunoprecipitation of lysates using the monoclonal sNKCC1 antibody (J3). Lysate in lanes labeled vector 1/PASK (a), sNKCC1/vector 2 (b), and sNKCC1/PASK (c) were combined 1:1 with HEK cell lysate before immunoprecipitation. In lane vector 1/PASK + sNKCC1/vector 2 (a + b), lysate from respective samples were combined before immunoprecipitation. The J3 blot shows the level of sNKCC1 immunoprecipitated from each sample. The HA blot represents the level of PASK immunoprecipitated with sNKCC1. Data are representative of three separate experiments. Lysate, lysates of sNKCC1/vector 2, vector 1/PASK, and sNKCC1/PASK cells subjected to SDS-PAGE and blotted for relative sNKCC1 (J3 blot) and PASK (HA blot) levels. The principal sNKCC1 band in the lysates is "washed out" in this blot due to substrate depletion in the Western blot exposure.

 

We have previously reported large regulatory differences between exogenously expressed hNKCC1 and endogenous NKCC bumetanide-sensitive 86Rb+ influx in HEK cells. The regulation of this endogenous NKCC1 in HEK cells differs greatly when compared with other mammalian and shark NKCCs investigated, both in native tissue and transfected cell systems (characterization of these phenomena are discussed in detail in Flemmer et al. (4) and Isenring et al. (19)). To address whether PASK regulates endogenous NKCC activity, we transfected a stable clonal cell line of HEK pcDNA3.1 empty vector with PASK or DNPASK. We found no alteration of endogenous NKCC flux by expression of PASK or DNPASK (data not shown). Similarly, there was no alteration in the R5 signal for phosphorylation of endogenous NKCC (Fig. 2A, right two lanes), adding yet another piece to the HEK-NKCC puzzle.

Although the identity of the NKCC1 regulatory kinase has not previously been reported, its characteristics and significance have been proposed. The critical step in the activation of NKCC1 appears to result from an increase in kinase(s) activity rather than a decrease in phosphatase activity or a conformational change in the cotransporter (2022). Lytle has termed this kinase the "CT", or cotransporter, kinase (21), and kinetic analysis suggests that it is autoactivated by low [Cl]i and/or cell volume (23). In this report, we show a 5.5-fold increase in PASK phosphorylation after preincubation in low [Cl]e. This increase is dependent upon the activity of PASK and possibly represents its intramolecular autophosphorylation, consistent with the theoretical requirements for the cotransporter kinase. Although not conclusive at this time, it is tempting to speculate that the increase in PASK phosphorylation shown in this report may also represent an increase in kinase activity.

The regulatory pathways of NKCCs and KCCs have been proposed to be linked due to their converse activation requirements (for review, see Ref. 24). The activity of the cotransporter kinase (adapted from Jennings and Al-Rohil v-kinase (25)) would, therefore, determine the set point for cell volume via reciprocal regulation of both NKCC and KCC. This set point has recently been reported to be modified by [Cl]i (23), making PASK-mediated regulation of both NKCC1 and KCC an attractive hypothesis.

As shown in Fig. 2 and described above, PASK mediates the phosphorylation of two threonines found within an N-terminal, regulatory domain. This domain is present and highly conserved in two proteins found in the distal tubule of the mammalian kidney, NKCC2 and the Na-Cl cotransporter (NCC); NKCC2 has also been reported to contain a PASK binding site (6). We propose that PASK may regulate the activity of NKCC2 and NCC and, therefore, play an important regulatory role in salt reabsorption and plasma fluid volume.

The data presented in this report strongly link PASK with the regulation of the secretory or housekeeping isoform of the Na-K-Cl cotransporter (NKCC1). We show that disruption of PASK activity, although not affecting the ability of kinase to bind NKCC1, results in up to an 80 ± 3% decrease in cotransport activity, as measured by 86Rb+ influx. Inhibition of PASK activity decreases total NKCC1 phosphorylation (32P incorporation) as well as the phosphorylation of the regulatory Thr184/Thr189 residues found within the N terminus (R5 binding). These data combined with the previously reported high expression level of PASK in solute transporting epithelial cells strongly suggest that this kinase plays an important role in the regulation of NKCC1 and, consequently, fluid secretion.


    FOOTNOTES
 
* The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

{ddagger} To whom correspondence should be addressed: Yale University, School of Medicine, Dept. of Cellular and Molecular Physiology, 333 Cedar St., New Haven CT 06520-0826. Tel.: 203-785-4068; Fax: 203-785-6834; E-mail: brian.dowd{at}yale.edu.

1 The abbreviations used are: NKCC1, Na-K-Cl cotransporter; sNKCC1, shark NKCC1; hNKCC1, human NKCC1; NCC, Na-Cl cotransporter; KCC, K-Cl cotransporter; PASK, proline-alanine-rich STE20-related kinase; DNPASK, dominant-negative (DN) PASK; MST, mammalian sterile twenty-like kinase; sMST1/2, shark MST; [Cl]e, extracellular chloride concentration; [Cl]i, intracellular chloride concentration; HEK, human embryonic kidney; vector 1, pJB20; vector 2, pIRES puro3; GST, glutathione S-transferase; HA, hemagglutinin. Back

2 Accession number O88506 [GenBank] , denoted as PASK in the original publication (7). The human homologue has also been termed SPAK (STE20/SPS1-related, proline alanine-rich kinase) (11). Back

3 Accession number AY242842 [GenBank] . This protein contains 83 and 79% identity to human MST1 and MST2 respectively. Back


    ACKNOWLEDGMENTS
 
We thank William Leiserson for the PASK cDNA clone (7), Grace Dillard for excellent technical work, and Brad Baker and Ignacio Giménez for helpful discussions. We also thank Dr. Baker, Dr. Giménez, and Meike Pedersen for comments on this manuscript.



    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS AND DISCUSSION
 REFERENCES
 

  1. Lytle, C., and Forbush, B., III (1992) J. Biol. Chem. 267, 25438–25443[Abstract/Free Full Text]
  2. Kurihara, K., Moore-Hoon, M. L., Saitoh, M., and Turner, R. J. (1999) Am. J. Physiol. 277, C1184–C1193[Medline] [Order article via Infotrieve]
  3. Darman, R. B., and Forbush, B. (2002) J. Biol. Chem. 277, 37542–37550[Abstract/Free Full Text]
  4. Flemmer, A. W., Gimenez, I., Dowd, B. F., Darman, R. B., and Forbush, B. (2002) J. Biol. Chem. 277, 37551–37558[Abstract/Free Full Text]
  5. Darman, R. B., Flemmer, A., and Forbush, B. (2001) J. Biol. Chem. 276, 34359–34362[Abstract/Free Full Text]
  6. Piechotta, K., Lu, J., and Delpire, E. (2002) J. Biol. Chem. 277, 50812–50819[Abstract/Free Full Text]
  7. Ushiro, H., Tsutsumi, T., Suzuki, K., Kayahara, T., and Nakano, K. (1998) Arch Biochem. Biophys. 355, 233–240[CrossRef][Medline] [Order article via Infotrieve]
  8. Klein, J. D., and O'Neill, W. C. (1995) Am. J. Physiol. 269, C1524–C1531[Medline] [Order article via Infotrieve]
  9. Fillon, S., Warntges, S., Matskevitch, J., Moschen, I., Setiawan, I., Gamper, N., Feng, Y. X., Stegen, C., Friedrich, B., Waldegger, S., Broer, S., Wagner, C. A., Huber, S. M., Klingel, K., Vereninov, A., and Lang, F. (2001) Comp. Biochem. Physiol. A. Mol. Integr. Physiol. 130, 367–376[CrossRef][Medline] [Order article via Infotrieve]
  10. Klein, J. D., Lamitina, S. T., and O'Neill, W. C. (1999) Am. J. Physiol. 277, C425–C431[Medline] [Order article via Infotrieve]
  11. Johnston, A. M., Naselli, G., Gonez, L. J., Martin, R. M., Harrison, L. C., and DeAizpurua, H. J. (2000) Oncogene 19, 4290–4297[CrossRef][Medline] [Order article via Infotrieve]
  12. Dan, I., Watanabe, N. M., and Kusumi, A. (2001) Trends Cell Biol. 11, 220–230[CrossRef][Medline] [Order article via Infotrieve]
  13. Leiserson, W. M., Harkins, E. W., and Keshishian, H. (2000) Neuron 28, 793–806[Medline] [Order article via Infotrieve]
  14. Matsuo, R., Ochiai, W., Nakashima, K., and Taga, T. (2001) J. Immunol. Methods 247, 141–151[CrossRef][Medline] [Order article via Infotrieve]
  15. Xu, J. C., Lytle, C., Zhu, T. T., Payne, J. A., Benz, E., Jr., and Forbush, B., III (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 2201–2205[Abstract]
  16. Payne, J. A., Xu, J. C., Haas, M., Lytle, C. Y., Ward, D., and Forbush, B., III (1995) J. Biol. Chem. 270, 17977–17985[Abstract/Free Full Text]
  17. Hanks, S. K., and Hunter, T. (1995) FASEB J. 9, 576–596[Abstract/Free Full Text]
  18. Lee, K. K., and Yonehara, S. (2002) J. Biol. Chem. 277, 12351–12358[Abstract/Free Full Text]
  19. Isenring, P., Jacoby, S. C., Payne, J. A., and Forbush, B., III (1998) J. Biol. Chem. 273, 11295–11301[Abstract/Free Full Text]
  20. Altamirano, A. A., Breitwieser, G. E., and Russell, J. M. (1995) Am. J. Physiol. 269, C878–C883[Medline] [Order article via Infotrieve]
  21. Lytle, C. (1998) Am. J. Physiol. 274, C1002–C1010[Medline] [Order article via Infotrieve]
  22. Lytle, C., and Forbush, B., III (1996) Am. J. Physiol. 270, C437–C448[Medline] [Order article via Infotrieve]
  23. Lytle, C., and McManus, T. (2002) Am. J. Physiol. Cell Physiol. 283, C1422–C1431[Abstract/Free Full Text]
  24. Haas, M., and Forbush, B., III (2000) Annu. Rev. Physiol. 62, 515–534[CrossRef][Medline] [Order article via Infotrieve]
  25. Jennings, M. L., and al-Rohil, N. (1990) J. Gen. Physiol. 95, 1021–1040[Abstract]